AbbVie Inc. (ABBV) Business Metric Overview - Stocknear

AbbVie Inc.

NYSE: ABBV · Real-Time Price · USD
212.52
-0.48 (-0.23%)
At close: Sep 05, 2025, 10:52 AM

AbbVie Revenue Breakdown

Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013
Botox Cosmetic Revenue 556M 687M 671M 729M 633M 718M 620M 685M 659M 642M 637M 695M 641M 626M 545M 584M 477M 493M 393M 226M 559M 628M 695M 780M 790M 2.6B 839M 108M 103M 100M 94M 81M 80M 78M 74M 73M 68M 62M 61M 55M 53M 56M 56M 56M 52M 88M 46M 44M 277M
Botox Cosmetic Revenue Growth -19.07% +2.38% -7.96% +15.17% -11.84% +15.81% -9.49% +3.95% +2.65% +0.78% -8.35% +8.42% +2.40% +14.86% -6.68% +22.43% -3.25% +25.45% +73.89% -59.57% -10.99% -9.64% -10.90% -1.27% -69.60% +209.77% +676.85% +4.85% +3.00% +6.38% +16.05% +1.25% +2.56% +5.41% +1.37% +7.35% +9.68% +1.64% +10.91% +3.77% -5.36% 0.00% 0.00% +7.69% -40.91% +91.30% +4.55% -84.12% n/a
Juvederm Collection Revenue 231M 279M 258M 343M 297M 334M 321M 368M 355M 322M 352M 344M 410M 432M 354M 428M 321M 331M 274M 113M 1.23B 1.3B 1.26B 1.1B 1.02B 1.01B 972M 5.18B 4.71B 4.89B 4.7B 4.72B 4.12B 4.29B 4.06B 4.15B 3.58B 3.72B 3.65B 3.54B 3.11B 9.29B 3.25B 393M 380M 671M 323M 395M n/a
Juvederm Collection Revenue Growth -17.20% +8.14% -24.78% +15.49% -11.08% +4.05% -12.77% +3.66% +10.25% -8.52% +2.33% -16.10% -5.09% +22.03% -17.29% +33.33% -3.02% +20.80% +142.48% -90.83% -4.94% +3.10% +14.38% +7.53% +1.59% +3.50% -81.25% +10.11% -3.74% +4.06% -0.32% +14.52% -4.05% +5.71% -2.15% +15.99% -3.77% +1.92% +3.11% +13.69% -66.51% +185.35% +728.24% +3.42% -43.37% +107.74% -18.23% n/a n/a
Other Aesthetics Revenue 315M 332M 310M 318M 319M 319M 298M 331M 286M 323M 312M 332M 323M 349M 352M 422M 343M 318M 300M 142M 317M 251M 221M 169M 151M 248M 96M 850M 762M 708M 688M 626M 551M 511M 501M 439M 381M 343M 304M 107M 303M 486M 370M n/a n/a n/a n/a n/a n/a
Other Aesthetics Revenue Growth -5.12% +7.10% -2.52% -0.31% 0.00% +7.05% -9.97% +15.73% -11.46% +3.53% -6.02% +2.79% -7.45% -0.85% -16.59% +23.03% +7.86% +6.00% +111.27% -55.21% +26.29% +13.57% +30.77% +11.92% -39.11% +158.33% -88.71% +11.55% +7.63% +2.91% +9.90% +13.61% +7.83% +2.00% +14.12% +15.22% +11.08% +12.83% +184.11% -64.69% -37.65% +31.35% n/a n/a n/a n/a n/a n/a n/a
Alphagan-Combigan Revenue 60M 78M 62M 49M 59M 66M 70M 65M 71M 74M 73M 92M 107M 141M 128M 142M 118M 134M 123M 69M 4.7B 4.92B 4.94B 4.87B 4.45B 4.92B 5.12B 151M 201M 231M 181M 289M 297M 289M 342M 309M 277M 302M 310M 308M n/a n/a n/a n/a n/a n/a n/a n/a n/a
Alphagan-Combigan Revenue Growth -23.08% +25.81% +26.53% -16.95% -10.61% -5.71% +7.69% -8.45% -4.05% +1.37% -20.65% -14.02% -24.11% +10.16% -9.86% +20.34% -11.94% +8.94% +78.26% -98.53% -4.35% -0.38% +1.36% +9.54% -9.60% -4.02% +3293.38% -24.88% -12.99% +27.62% -37.37% -2.69% +2.77% -15.50% +10.68% +11.55% -8.28% -2.58% +0.65% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Lumigan-Ganfort Revenue 106M 119M 116M 103M 91M 92M 91M 119M 130M 123M 121M 130M 140M 149M 138M 149M 143M 153M 149M 76M 86M 216M 91M 48M 111M 113M 106M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Lumigan-Ganfort Revenue Growth -10.92% +2.59% +12.62% +13.19% -1.09% +1.10% -23.53% -8.46% +5.69% +1.65% -6.92% -7.14% -6.04% +7.97% -7.38% +4.20% -6.54% +2.68% +96.05% -11.63% -60.19% +137.36% +89.58% -56.76% -1.77% +6.60% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Eye Care Revenue 217M 215M 207M 225M 200M 181M 207M 215M 200M 283M 287M 327M 278M 306M 286M 301M 276M 296M 269M 128M 300M 118M 117M 115M 114M n/a 25M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Eye Care Revenue Growth +0.93% +3.86% -8.00% +12.50% +10.50% -12.56% -3.72% +7.50% -29.33% -1.39% -12.23% +17.63% -9.15% +6.99% -4.98% +9.06% -6.76% +10.04% +110.16% -57.33% +154.24% +0.85% +1.74% +0.88% n/a -100.00% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Ozurdex Revenue 123M 120M 119M 124M 131M 118M 120M 119M 115M 1.11B 1.14B 1.15B 1.17B 1.39B 1.37B 1.38B 1.27B 1.42B 1.37B 1.29B 124M 60M 83M 254M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Ozurdex Revenue Growth +2.50% +0.84% -4.03% -5.34% +11.02% -1.67% +0.84% +3.48% -89.69% -1.76% -0.87% -2.39% -15.31% +0.80% -0.51% +8.91% -10.96% +3.94% +6.37% +938.71% +106.67% -27.71% -67.32% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Imbruvica Revenue 738M 848M 828M 833M 838M 903M 908M 907M 878M 516M 515M 505M 473M 488M 492M 435M 405M 365M 352M 303M 105M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Imbruvica Revenue Growth -12.97% +2.42% -0.60% -0.60% -7.20% -0.55% +0.11% +3.30% +70.16% +0.19% +1.98% +6.77% -3.07% -0.81% +13.10% +7.41% +10.96% +3.69% +16.17% +188.57% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
VENCLEXTA Revenue 665M 655M 677M 637M 614M 589M 590M 571M 538M 5.58B 5.56B 5.36B 4.74B 5.33B 5.42B 5.07B 4.87B 5.15B 5.14B 4.84B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
VENCLEXTA Revenue Growth +1.53% -3.25% +6.28% +3.75% +4.24% -0.17% +3.33% +6.13% -90.36% +0.36% +3.65% +13.24% -11.21% -1.68% +7.04% +4.13% -5.53% +0.23% +6.26% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
H U M I R A Revenue 1.12B 1.68B 2.23B 2.81B 2.27B 3.3B 3.55B 4.01B 3.54B 770M 695M 592M 465M 517M 453M 378M 303M 281M 215M 149M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
H U M I R A Revenue Growth -33.35% -24.47% -20.86% +23.96% -31.30% -6.85% -11.59% +13.30% +359.87% +10.79% +17.40% +27.31% -10.06% +14.13% +19.84% +24.75% +7.83% +30.70% +44.30% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
RINVOQ Revenue 1.72B 1.83B 1.61B 1.43B 1.09B 1.25B 1.11B 918M 686M 1.58B 1.4B 1.25B 940M 895M 796M 674M 574M 525M 435M 330M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
RINVOQ Revenue Growth -6.32% +13.63% +12.87% +30.83% -12.91% +13.06% +20.92% +33.82% -56.47% +12.81% +11.58% +33.19% +5.03% +12.44% +18.10% +17.42% +9.33% +20.69% +31.82% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
SKYRIZI Revenue 3.42B 3.78B 3.21B 2.73B 2.01B 2.39B 2.13B 1.88B 1.36B 728M 699M 678M 614M 671M 645M 603M 532M 567M 523M 297M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
SKYRIZI Revenue Growth -9.34% +17.88% +17.53% +35.81% -16.12% +12.61% +12.90% +38.46% +86.81% +4.15% +3.10% +10.42% -8.49% +4.03% +6.97% +13.35% -6.17% +8.41% +76.09% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Botox Therapeutic Revenue 866M 873M 848M 814M 748M 776M 748M 748M 719M 107M 110M 120M 121M 128M 127M 127M 129M 129M 123M 118M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Botox Therapeutic Revenue Growth -0.80% +2.95% +4.18% +8.82% -3.61% +3.74% 0.00% +4.03% +571.96% -2.73% -8.33% -0.83% -5.47% +0.79% 0.00% -1.55% 0.00% +4.88% +4.24% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Duodopa Revenue 96M 108M 111M 113M 115M 115M 118M 117M 118M 61M 87M 150M 177M 183M 171M 171M 160M 227M 207M 105M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Duodopa Revenue Growth -11.11% -2.70% -1.77% -1.74% 0.00% -2.54% +0.85% -0.85% +93.44% -29.89% -42.00% -15.25% -3.28% +7.02% 0.00% +6.88% -29.52% +9.66% +97.14% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Neuroscience Revenue 59M 100M 84M 80M 74M 66M 61M 70M 79M 269M 271M 255M 240M 287M 261M 268M 222M 286M 248M 133M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Neuroscience Revenue Growth -41.00% +19.05% +5.00% +8.11% +12.12% +8.20% -12.86% -11.39% -70.63% -0.74% +6.27% +6.25% -16.38% +9.96% -2.61% +20.72% -22.38% +15.32% +86.47% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Qulipta Revenue 193M 201M 176M 150M 131M 180M 132M 96M 152M 380M 383M 398M 380M 427M 426M 442M 415M 481M 414M 376M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Qulipta Revenue Growth -3.98% +14.20% +17.33% +14.50% -27.22% +36.36% +37.50% -36.84% -60.00% -0.78% -3.77% +4.74% -11.01% +0.23% -3.62% +6.51% -13.72% +16.18% +10.11% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Ubrelvy Revenue 240M 303M 269M 231M 203M 234M 233M 196M 561M 992M 925M 1.01B 1.21B 594M 547M 640M 892M 1.4B 829M 590M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Ubrelvy Revenue Growth -20.79% +12.64% +16.45% +13.79% -13.25% +0.43% +18.88% -65.06% -43.45% +7.24% -8.33% -16.68% +103.87% +8.59% -14.53% -28.25% -36.24% +68.76% +40.51% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Vraylar Revenue 765M 924M 875M 774M 694M 789M 751M 658M 259M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Vraylar Revenue Growth -17.21% +5.60% +13.05% +11.53% -12.04% +5.06% +14.13% +154.05% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Linzess-Constella Revenue 148M 233M 234M 221M 266M 283M 288M 278M 364M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Linzess-Constella Revenue Growth -36.48% -0.43% +5.88% -16.92% -6.01% -1.74% +3.60% -23.63% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
MAVYRET Revenue 306M 291M 302M 369M 349M 309M 370M 387M 691M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
MAVYRET Revenue Growth +5.15% -3.64% -18.16% +5.73% +12.94% -16.49% -4.39% -43.99% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Products Revenue 747M 752M 726M 810M 744M 821M 782M 741M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Other Products Revenue Growth -0.66% +3.58% -10.37% +8.87% -9.38% +4.99% +5.53% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

Revenue by Geography

Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Non-Us Revenue 9.98B 11.73B 3.31B 3.36B 3.27B 11.11B 3.08B 3.15B 3.02B 2.93B 3.05B 3.17B 3.19B 3.21B 3.06B 3.15B 3.26B 3.19B 2.99B 2.28B 6.16B 10.87B 1.05B 2.05B 1.23B 11.45B 1.58B 3.52B 3B
Non-Us Revenue Growth -14.96% +254.29% -1.31% +2.66% -70.58% +261.30% -2.23% +4.00% +3.24% -3.94% -3.91% -0.53% -0.59% +4.77% -2.92% -3.22% +2.10% +6.68% +31.39% -63.01% -43.34% +936.13% -48.75% +66.29% -89.25% +625.86% -55.18% +17.25% n/a
United States Revenue 3.36B 3.37B 11.15B 11.11B 9.04B 3.19B 10.85B 10.72B 9.2B 12.19B 11.76B 11.41B 10.35B 11.68B 11.28B 10.8B 9.75B 10.66B 9.91B 8.15B 2.46B n/a 3.89B 5.94B 3.21B n/a 3.55B 1.66B 1.71B
United States Revenue Growth -0.12% -69.79% +0.38% +22.84% +183.33% -70.60% +1.23% +16.51% -24.53% +3.65% +3.09% +10.26% -11.38% +3.53% +4.40% +10.81% -8.58% +7.63% +21.63% +231.04% n/a n/a -34.52% +84.63% n/a n/a +113.10% -2.46% n/a

Operating Expense Breakdown

Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selling, General, and Administrative Revenue 3.22B 3.29B 2.88B 4.21B 3.38B 3.31B 3.19B 3.37B 3.27B 3.04B 3.42B 3.3B 5.41B 3.13B 3.26B 3.08B 3.07B 2.84B 3.23B 2.85B 3.53B 1.7B 1.95B 1.66B 1.65B 1.68B 1.93B 1.92B 1.76B 1.79B 1.57B 1.45B 1.5B 1.37B 1.65B 1.38B 1.47B 1.35B 1.74B 1.47B 1.7B 1.47B
Selling, General, and Administrative Revenue Growth -2.28% +14.38% -31.53% +24.52% +1.87% +3.82% -5.31% +3.18% +7.54% -11.06% +3.42% -38.95% +73.07% -4.08% +5.74% +0.36% +8.09% -12.04% +13.53% -19.31% +108.08% -13.12% +17.74% +0.18% -1.55% -12.91% +0.52% +9.03% -1.73% +13.86% +8.33% -3.46% +9.94% -17.24% +19.70% -5.80% +8.19% -21.99% +17.84% -13.45% +15.61% n/a
Research and Development Revenue 2.1B 2.07B 6.77B 2.13B 1.95B 1.94B 2.21B 1.72B 1.73B 2.29B 2.03B 1.61B 1.88B 1.64B 2.23B 2.06B 1.9B 1.85B 2.19B 1.71B 2.44B 1.38B 1.68B 2.29B 1.38B 1.44B 6.79B 1.32B 1.32B 1.24B 1.4B 1.22B 1.22B 1.14B 1.19B 1.11B 1.12B 946M 1.07B 1.42B 981M 811M
Research and Development Revenue Growth +1.60% -69.49% +218.03% +9.34% +0.46% -12.22% +28.21% -0.58% -24.39% +12.74% +25.96% -14.06% +14.37% -26.43% +8.19% +8.64% +2.54% -15.43% +28.37% -29.94% +76.58% -17.97% -26.43% +65.34% -4.29% -78.75% +413.61% +0.08% +6.27% -11.27% +14.73% -0.08% +7.75% -4.62% +7.59% -1.60% +18.82% -12.00% -24.19% +44.55% +20.96% n/a